Karl W. Patterson
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
The broad societal value of pembrolizumab for women's cancer in Canada.
Journal: Future oncology (London, England)
Published: March 13, 2026
Impact of early-stage immunotherapy on health and work productivity in the Czech Republic, 2024-2033.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: February 24, 2026
Health and productivity benefits of anti-PD-(L)1 agents for early-stage cancer treatment in Hungary.
Health and productivity benefits of anti-PD-(L)1 agents for early-stage cancer treatment in Hungary.
Journal: Journal of medical economics
Published: February 18, 2026
Evaluating the broad societal value of pembrolizumab in women's cancer in Brazil.
Journal: Journal of medical economics
Published: September 17, 2025
Modelling Treatment Sequences in Immunology: Optimizing Patient Outcomes.
Journal: Advances in therapy
Published: November 13, 2023
Targeted literature review exploring the predictive value of estimated glomerular filtration rate and left ventricular mass index as indicators of clinical events in Fabry disease.
Journal: Orphanet journal of rare diseases
Published: July 17, 2023
Adapting lean methodology towards surgical tray rationalisation in inguinoscrotal day case surgery in the republic of Ireland.
Journal: Journal of pediatric urology
Published: October 20, 2022
Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States.
Journal: Clinical genitourinary cancer
Published: April 29, 2020
"Stick or Twist?" Negotiating Price and Data in an Era of Conditional Approval.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: January 07, 2019
Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.
Journal: European urology oncology
Published: May 14, 2018
Human CDK18 promotes replication stress signaling and genome stability.
Journal: Nucleic acids research
Published: December 07, 2015
Altered RECQL5 expression in urothelial bladder carcinoma increases cellular proliferation and makes RECQL5 helicase activity a novel target for chemotherapy.
Journal: Oncotarget
Published: September 08, 2015
Last Updated: 09/26/2026